HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Humoral immune depression following autologous stem cell transplantation is a marker of prolonged response duration in patients with mantle cell lymphoma.

Abstract
Rituximab maintenance (RM) after autologous stem cell transplantation (ASCT) is standard-of-care for young patients with mantle cell lymphoma (MCL). RM may enhance post-transplantation immune depression and risk of infections. We compared infection incidence and immune consequences of RM versus observation in transplanted MCL patients. All randomized patients included in the LyMa trial were eligible. The following parameters were collected prospectively: occurrence of fever, infection, hospitalization, neutropenia, hypogammaglobulinemia, CD4 lymphopenia and γ globulin (Ig) substitution. The post-ASCT period was divided into four periods in order to assess the possible effects of RM or ASCT on immune status. Each arm included 120 patients. Concerning infection incidence and all biological parameters, there was no difference between the two arms during the first year post ASCT. After this period, RM patients were more exposed to fever (P=0.03), infections (P=0.001), hypogammaglobulinemia (P=0.0001) and Ig substitution (P<0.0001). Incidences of hospitalization, neutropenia and CD4 lymphopenia were not different between the two arms. The number of rituximab injections was correlated with infections and hypogammaglobulinemia, P<0.0001 and P=0.001; but was not correlated with neutropenia and CD4 lymphopenia. Ig substitution did not modify infection incidence. Patients who presented hypogammaglobulinemia <6 g/L or <4 g/L had longer 3-years progression-free survival (PFS), this applies to RM patients (P=0.012 and P=0.03) and to the global cohort (P=0.008 and P=0.003). Hypogammaglobulinemia did not influence overall survival. Occurrence of infectious event, neutropenia and CD4 lymphopenia did neither influence PFS nor overall survival. Post-ASCT RM in MCL patients causes sustained hypogammaglobulinemia, which is independently correlated with improved PFS.
AuthorsLouise Bouard, Benoit Tessoulin, Catherine Thieblemont, Kamal Bouabdallah, Thomas Gastinne, Lucie Oberic, Sylvain Carras, Caroline Delette, Olivier Casasnovas, Caroline Dartigeas, Victoria Cacheux, Sibylle Masse, Olivier Hermine, Steven Le Gouill
JournalHaematologica (Haematologica) Vol. 107 Issue 9 Pg. 2163-2172 (09 01 2022) ISSN: 1592-8721 [Electronic] Italy
PMID35172560 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Rituximab
Topics
  • Adult
  • Agammaglobulinemia (etiology)
  • Antineoplastic Combined Chemotherapy Protocols (adverse effects)
  • Depression
  • Hematopoietic Stem Cell Transplantation (adverse effects)
  • Humans
  • Lymphoma, Mantle-Cell (drug therapy)
  • Lymphopenia (etiology)
  • Neutropenia
  • Rituximab (therapeutic use)
  • Stem Cell Transplantation
  • Transplantation, Autologous (adverse effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: